Replies to post #106395 on Biotech Values

[rwwine]

Given we are still two weeks away from the start of the AASLD conference, I'm more inclined to think that some investors felt the "intrinsic value" of the company as a whole depreciate too much since the FDA hold and have been accumulating for a while. Just my 2 cents.